BILLERICA, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell patient-specific knee and hip joint replacement implants designed to fit each patient’s unique anatomy, today announced that the Orthopaedic Data Evaluation Panel in the United Kingdom (ODEP) (http://www.odep.org.uk) awarded the Conformis iTotal® CR knee replacement system a “5A” rating. The 5A rating is based on strong evidence of implant performance over five years, including low revision rates as indicated in the UK’s National Joint Registry (NJR).
ODEP is an independent panel of leading orthopedic surgeons and experts in the UK that evaluates data related to use of hip and knee implant technologies and provides a rating to indicate performance in key areas including survivorship. ODEP provides the National Health Service (NHS) with an approved list of products that meet the revision rate standard set by the National Institute for Health and Care Excellence (NICE) in the UK. The 5A rating (as explained in more detail at http://www.odep.org.uk/ODEPExplained.aspx#2) is based on five-year performance data. ODEP ratings provide a simple, independently verified assessment as to the performance of an implant, assessed against national clinical best practice guidelines. This enables clinicians to ensure that the implants that they use comply with these national guidelines. Only products that demonstrate compliance with NICE guidance are awarded a rating. To date, more than 65 surgeons in the UK have implanted over 1,000 iTotal® CR implants with a five-year cumulative revision rate of 1.8% versus 2.2% for all other total knee replacements in the NJR.
“I am delighted that ODEP recognise what myself and other Conformis users know already. The rating, I hope, will help reassure patients and surgeons in their decision making process for knee arthroplasty.” – Stuart Roy – Spire Cardiff Hospital and Royal Glamorgan Hospital, Wales.
“The news that the Conformis iTotal®-CR knee prosthesis has now been awarded an ODEP 5A rating comes as no surprise to me. Since I first started using Conformis knees back in 2012, I have seen a very significant improvement in outcomes for my knee replacement patients, with happier patients having better knee movement and significantly better function. Patient conforming knees are, in my opinion, by far the best type of knee replacement on the market, by a mile – and pretty much every knee replacement I do now is patient conforming.” – Ian McDermott – London Bridge Hospital.
“We are pleased to have received the ODEP 5A rating,” said Mark Augusti, Chief Executive Officer and President of Conformis. “This rating provides another independent verification that our design philosophy, predicated on patient-conforming implants, results in performance where it counts the most—in patients. We hope that this 5A rating will provide more confidence to physicians that are considering offering our unique technology to their patients. In addition, we believe our results should provide an opportunity for Conformis to expand availability of our product at NHS facilities in the United Kingdom.”
About Conformis, Inc.
Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell patient-specific joint replacement implants (individually sized and shaped, or personalized, to fit each patient’s unique anatomy). Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to the hospital. In clinical studies, the Conformis iTotal CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover customized implants and customized patient-specific instrumentation for all major joints.
Statements in this press release about our future expectations, plans and prospects, including statements about the anticipated timing of our product launches, and our financial position and results, total revenue, product revenue, gross margin, operations and growth, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual financial results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to our estimates and expectations regarding our revenue, gross margin, expenses, revenue growth and other results of operations, and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.